Posted by Michael Wonder on 03 Dec 2020
Lilly announces 650,000 additional doses of neutralising antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19
2 December 2020 - The U.S. government has purchased 650,000 additional doses of Eli Lilly and Company's neutralising antibody bamlanivimab (LY-CoV555) 700 mg.
The purchase agreement is for $812.5 million and the doses will be delivered through January 31, 2021, with at least 350,000 of the additional doses delivered in December 2020.
